A US judge on Friday approved Bayer's $7.25 billion settlement of lawsuits over claims its Roundup weedkiller caused blood cancer, as the German agri giant seeks to draw a line under years of costly litigation.
The Missouri state court "fully and finally approves the Settlement Agreement in its entirety," Judge Timothy Boyer said in his ruling.
It is among the largest class recoveries in US history, and clears the way for guaranteed compensation for tens of thousands of Roundup cancer victims.
Bayer has spent billions of dollars settling thousands of cases linked to Roundup since it acquired the weedkiller's producer, the US agrichemical group Monsanto, in 2018.
Christopher Seeger, a court-appointed attorney for plaintiffs in the settlement, said in a statement: "Today's final approval order delivers guaranteed compensation to Roundup cancer victims who have waited more than a decade for justice."
But he added that the path to successful litigation had "narrowed" since the US Supreme Court held in June that Bayer should be shielded from so-called failure-to-warn claims in US states, because the federal government said Roundup could be sold without a warning label.
The International Agency for Research on Cancer considers glyphosate, Roundup's main active ingredient, a probable human carcinogen, but Bayer says scientific studies and regulatory approvals show the weedkiller is safe.
Last year, a highly influential decades-old study that declared Roundup posed no serious health risks was retracted, ending a 25-year saga that exposed how corporate interests can distort scientific research and influence government decision-making.
In a retraction note, the journal Regulatory Toxicology and Pharmacology cited a litany of serious flaws, ranging from the omission of carcinogenicity studies available at the time to undisclosed contributions by Monsanto employees and questions over financial compensation.
ia/jgc